Shifts in treatment initiation patterns among newly diagnosed multiple sclerosis patients in Germany: a claims data analysis from 2017 to 2022
Open Access
- 17 April 2025
- journal article
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 18
Abstract
Background: Early use of high-efficacy therapies (EHT) in multiple sclerosis (MS) is a promising but novel treatment strategy. Its adoption in Germany’s MS care warrants further research. Objectives: This study assessed treatment initiation patterns among newly diagnosed MS patients in Germany (2017–2022). Design: This is a retrospective observational study. Methods: Claims data from 4.5 million individuals insured by German statutory health insurance included 1448 newly diagnosed MS patients from 2017 to 2022. Patients were identified by International Statistical Classification of Diseases and Related Health Problems, 10th revision, German modification (ICD-10-GM) code G35 – in two different quarters of the same year, and a disease-modifying therapy (DMT) prescription, with no prior MS diagnosis or DMT prescription in the preceding 2 years. DMTs were categorized according to German Society of Neurology S2k guidelines: category 1 (low-efficacy), category 2 (moderate-efficacy) and category 3 (high-efficacy). Results: Of patients initiating treatment, 77.1% started with category 1, 8.1% with category 2 and 14.8% with category 3 DMTs. From 2017 to 2022, category 1 initiations declined by 7.6% points (pp), while categories 2 and 3 initiations increased by 2.8 and 4.8 pp, respectively. Escalation to category 3 occurred in 10.5% of category 1/2 starters, with 31.5% taking over 2 years. De-escalation to category 1/2 occurred in 3.3% of category 3 starters. Conclusion: Real-world data highlight a shift towards EHT in MS care.Keywords
This publication has 23 references indexed in Scilit:
- Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosisMultiple Sclerosis and Related Disorders, 2024
- Multiple sclerosis: time for early treatment with high-efficacy drugsJournal of Neurology, 2023
- Trends in administrative prevalence of multiple sclerosis and utilization patterns of disease modifying drugs in GermanyMultiple Sclerosis and Related Disorders, 2022
- Multiple sclerosis by phenotype in GermanyMultiple Sclerosis and Related Disorders, 2022
- Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple SclerosisJAMA Neurology, 2021
- Early Aggressive Treatment Approaches for Multiple SclerosisCurrent Treatment Options in Neurology, 2021
- Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World StudyNeurotherapeutics, 2020
- Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple SclerosisJAMA, 2019
- Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future DirectionsNeurotherapeutics, 2017
- Concepts of induction and escalation therapy in multiple sclerosisJournal of the Neurological Sciences, 2009